Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT04093505
Title Gemtuzumab Ozogamicin in Induction and Glasdegib in Postremission Therapy in Patients With AML (Acute Myeloid Leukemia) (GnG)
Acronym GnG
Recruitment Terminated
Gender both
Phase Phase III
Variant Requirements No
Sponsors University Hospital Heidelberg
Age Groups: adult | senior
Covered Countries DEU

No variant requirements are available.